CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Net sales	$ 1,385.9	$ 1,295.5	$ 2,732.8	$ 2,533.2
Cost of sales	285.3	256.9	581.6	495.9
Gross profit	1,100.6	1,038.6	2,151.2	2,037.3
Selling, general, and administrative expenses	450.8	410.4	883.6	792.4
Research and development expenses	272.6	243.7	530.4	478.5
Intellectual property agreement and certain litigation expenses (Note 3)	8.1	147.9	17.0	191.4
Change in fair value of contingent consideration liabilities (Note 7)	0.0	(26.9)	0.0	(26.2)
Operating income, net	369.1	263.5	720.2	601.2
Interest income, net	(15.5)	(9.1)	(32.0)	(17.7)
Other income, net	(2.0)	(2.5)	(7.7)	(3.7)
Income from continuing operations before provision for income taxes	386.6	275.1	759.9	622.6
Provision for income taxes	20.2	20.9	66.8	66.2
Net income from continuing operations	366.4	254.2	693.1	556.4
(Loss) income from discontinued operations, net of tax	(1.4)	51.3	22.9	89.6
Net income	365.0	305.5	716.0	646.0
Net loss attributable to noncontrolling interest	(1.3)	(1.6)	(2.2)	(1.6)
Net income attributable to Edwards Lifesciences Corporation	$ 366.3	$ 307.1	$ 718.2	$ 647.6
Basic:
Continuing operations (in dollars per share)	$ 0.61	$ 0.42	$ 1.15	$ 0.92
Discontinued operations (in dollars per share)	0	0.09	0.04	0.15
Basic earnings per share (in dollars per share)	0.61	0.51	1.19	1.07
Diluted:
Continuing operations (in dollars per share)	0.61	0.42	1.15	0.91
Discontinued operations (in dollars per share)	0	0.08	0.04	0.15
Diluted earnings per share (in dollars per share)	$ 0.61	$ 0.50	$ 1.19	$ 1.06
Weighted-average number of common shares outstanding:
Basic (in shares)	602.1	606.9	601.8	607.2
Diluted (in shares)	604.3	610.3	604.2	610.6